Infosys Limited vs Vir Biotechnology Inc. Common Stock — how do they compare? Infosys Limited trades at $11.67 (market cap $44.92B), while Vir Biotechnology Inc. Common Stock trades at $10.2 (market cap $1.80B). The key difference: Infosys Limited is far larger — about 25× Vir Biotechnology Inc. Common Stock's market cap, and Infosys Limited pays a 4.59% dividend while Vir Biotechnology Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Infosys Limited for 26 Days and Vir Biotechnology Inc. Common Stock for 0 Days on average.
| INFY | VIR | |
|---|---|---|
Market Cap | $44.92B | $1.80B |
Volume | 25,564,570 | 1,782,836 |
Sector | Technology | Health |
52-Week High | $20.22 | $11.78 |
52-Week Low | $10.49 | $5.12 |
Typical Hold Time | 26 Days | 0 Days |
Enterprise Value | $42.66B | $1.36B |
Dividend Yield | 4.59% | — |
Signals from Pluang's Aura AI — not financial advice
INFY trades at $11.40, up 5.26% today, with a bullish technical signal driven by oversold RSI conditions. The company reported strong earnings beats in recent quarters, with Q1 2026 EPS of $0.23 exceeding expectations. Revenue for 2025 was $19.28B, with a net income margin of 16.37%. Recent news highlights strategic AI collaborations with Columbia University and ABN Amro, positioning the firm for innovation-driven growth.
The outlook is cautiously optimistic, supported by solid profitability and strategic partnerships, but tempered by a mixed analyst consensus and potential net cash flow decline in 2026. Key risks include competitive pressures in IT services and macroeconomic sensitivity. The consensus price target of $11.48 suggests limited near-term upside from current levels.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Infosys is a global leader in next-generation digital services and consulting. It enables clients in more than 50 countries to navigate their digital transformation through AI-powered cloud and data solutions.
Read more on INFY →Vir Biotechnology, Inc. is a US clinical-stage biopharmaceutical company that develops monoclonal antibody-based medicines to treat and prevent serious infectious diseases.
Read more on VIR →